Standardization of antifungal susceptibility testing: Review update

Revista Iberoamericana de Micologia

Volumn 13, Issue SUPPL. 1, 1996, Pages

  Espinel Ingroff, Ana ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antifungal; Guidelines; Susceptibility; Testing

Indexed keywords

EID: 0002672828     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Espinel-Ingroff A A history of medicalmycology in the United States 1996. J Clin Microbiol, April
2. Beck-Sague CM Jarvis WR, the National Nosocomial Infections Surveillance System Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990 J Inf Dis 1993, 167 1247-1251
3. Bryce EA, Roberts FJ, Sekhon AS, Coldman A Yeast in blood cultures evaluation of factors influencing outcome Diagn Microbiol Infect Dis 1992 15 233-237
4. Price MF, LaRocco MT, Gentry LO Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period Antimicrob Agents Chemoter 1994 38 1422-1424
5. Wey SB, Mori M, Pfaller MA Woolson RF, Wenzel RP Hospital acquired candidemia: the attributable mortality and excess length of stay Arch Intern Med 1988, 148 2642-2645
6. Wingard, JR. Importance of Candida species other than C albicans as pathogens in oncology patients Clin Infect Dis 1995, 20 115-125
7. Wingard JR Merz WG, Rinaldi MG Hohnson TR, Karp JE Saral R Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole N Engl J Med 1991 325 1274-1277
8. Dick D, Merz WG Saral R Incidence of polyene-resistant yeasts recovered from clinical specimens Antimicrob Agents Chemother 1980 18 158-163
9. Hazen KC New and emerging yeast pathogens Clin Microbiol Rev 1995, 8 462-478
10. Espinel-Ingroff A, Shadomy S In vitro and in vivo evaluation of antifungal agents Eur J Clin Microb Inf Dis 1989 8.352-361
11. Hadfiels TL, Smith MB, Winn RE, Rinaldi MG Guerra C Mycoses caused by Candida lusitaniae Rev Infect Dis 1987 9 1006-1012
12. Powderly WG, Kobayashi GS, Herzig GP, Medoff G Amphotericin B-resistant yeast infection in severely immunocompromised patients Am J Med 1988, 84 826-832
13. Warnock DW, Burke J Cope NJ, Johnson EM, vonFraunhofer NA, Williams EW. Fluconazole resistance in Candida glabrata Lancet 1988 ii 1310
14. Anaissie EJ Bodey GP Rinaldi MG Emerging fungal pathogens Eur J Clin Microbiol Infect Dis 1989, 8 323-330
15. Anaissie EJ, Bodey GP. Disseminated trichosporonosis Meeting the challenge Eur J Clin Microbiol Infect Dis 1991. 10 711-713
16. Supparatpinyo K Nelson KE, Merz WG, Breslin BJ, Cooper CR Kanwan CT Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens Antimicrcb Agents Chemother 1993, 37 2407-2411
17. Bradsher RW Blastomycosis Clinical Inf Dis 1992. (Suppl 1) 14 S82-90
18. Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, Galgiani JN, Graybill JR, Sugar AM, Catanzaro A, Gallis H, Perfect JR, Dockery B, Dismukes WE Stevens DA NIAID mycoses study group multicenter trial of oral itraconazole therapy of invasive aspergillosis Am Med 1994, 97 135-144
19. Galgiani JN Catanzaro A, Cloud GA, Higgs J, Friedman BA, LArsen RA, GRaybill JR, NIAID-MSG Fluconazole therapy for coccidioidal meningitis Ann Intern Med 1993, 119 28-35
20. Graybill JH, Stevens DA, Galgiani JN, Dismukes WE, Cloud GA. NIAID-MSG Itrazonazole treatment of coccidioidomycosis Am J Med 1990, 89 282-290
21. Powderly WG Therapy for cryptococcal meningitis in patients with AIDS Clin Inf Dis 1992, (Suppl. 1) 14 S54-S59
22. Sarosi GA Johnson PC Disseminated histoplasmosis in patients infected with human immunodeficiency virus Clin Inf Dis 1992, (Suppl 1) 14 S54-559
23. Wheat LJ Histoplasmosis in Indianapolis Clin Inf Dis 1992. (Suppl 1) 14 S91-99
24. Espinel-Ingroff A, Pfaller M Antifungal agents ans susceptibility testing En PK Murray, EJ Baron, MA Pfaller, FC Tenover, RH Yolken (ed ), Manual of Clinical Microbiology, 6th ed American Society for Microbiology Washington D C 1995, 1405-1421
25. Fromtling RA Overview of medically important antifungal azole derivatives Clin Microbiol Rev 1988 1:187-217
26. Saag MS, Dismukes WE Azole antifungal agents' emphasis on new triazoles Antimicrob Agents Chemother 1988, 32 1-8
27. Akova M, Akalin HE, Uzun O, Gur D Emergence of Candida kruser infections after therapy of oropharyngeal candidiasis with fluconazole Eur J Clin Microbiol Infect Dis 1991 10 598-599
28. Reeding S, Smith J, Fannacci G Rinaldi M, Fothergill A Rhine-Chalberg J, Pfaller M Development of resistance to Iluconazose by Candida albicans during treatment of oropharyngeal candidiasis in AIDS Documentation by in vitro susceptibility testing and DNA subtype analysis Clin Infect Dis 1994, 18 240-242
29. Dismukes WE, Cloud G, Gallis HA, Kerkering TM, Medoff G, and the National Institute of Allergy and Infectious Diseases Mycoses Study Group. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987, 317 334-341
30. Rex JH, Cooper CR Jr, Merz WG, Galgiani JN, Anaissie EJ Detection of amphoterictn B-resistant Candida species in a broth-based system. Antimicrob Agents Chemother 1995, 39 906-909
31. Polak A, Scholer HJ. Mode of action of 5-flurocytosine and mechanisms of resistance Chemotherapy 1975. 21 113-130
32. Lutwick LI Rytel MW, Yanez JP. Galgiani JN, Stevens DA Deep infections from Petriellidium boydii treated with miconazole J Am Med Assoc 1979, 241:272-273
33. Dismukes WE, Stamm AM, Graybiil JR, Craven PC, Stevsns DA, Stiller RL, Sarosi GA. Medoff G, Gregg CR, Gallis HA, Fields BT Jr, Marier RL, Kerkering TM, Kaplowitz LG, Cloud G, Bowles C, Shadomy S Treatment of systemic mycoses with ketoconazole emphasis on toxicity and clinical response in 52 patients Ann Intern Med 1983, 98 13-20
34. Powderly WG, Saag MS, Cloud GA, Robinson P, Meyor RD, Jacobson JM, Graybill JR, Sugar AM, McAuliffe VJ, Follansbee SE, Tuazon CU, Stern JJ, Feinberg J, Hafner R, Dismukes WE, the NIAID AIDS Clinical Trials Group, the NIAID-MSG. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome N Engl J Med 1992, 326 793-798
35. Saag MS, Powderly WG Cloud GA, Robinson P, Grieco MH, Sharkey PK, Thompson SE, Sugar AM, Tuazon CU, Fisher JF Hyslop N, Jacobson JM, Hafner R, Dismukes WE, the NIAID-MSG, the AIDS Clinical Trials Group Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992. 33ç26 83-89
36. Dismukes WE, Bradsher RW, Cloud GC, Kauffman CA, and the NIAID Mycoses Study Group Itraconazole therapy for blastomycosis and histoplasmosis Am J Med 1992, 93 489-497
37. Sharkey-Mathis PK, Kauffman CA, Graybill JR, Stevens DA Hosteller JS, Cloud G, Dismukes WE the NIAID-MSG Treatment of sporotrichosis with itraconazole Am J Med 1993, 95 279-285
38. Calhoun DL, Roberts GD, Galgiani N, Bennett JE, Feingold DS, Jorgensen J, Kobayashi JS, Shadomy S. Results of a survey of antifungal susceptibility tests in the United States and laboratory comparison of broth dilution testing of flucytosine and amphotericin B J Clin Microbiol 1988, 23 298-301
39. Galgiani JN Why not standardize antifungal susceptibility testing? Antimicrob Newsl 1984, 1:40
40. Galgiani JN, Reiser J, Brass C, Espinel-Ingroff A, Gordon MA, Kekering TM Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods Antimicrob Agents Chemother 1987, 31 1343-1347
41. Espinel-Ingroff A, Kish CW Jr, Kerkering TM, Fromtling RA, Sartizal K, Galgiani JN, Villareal K, Pfaller MA, Gerarden T, Rinaldi MG Fothergill A Collaborative comparison of broth macrodilution and microdiution antifungal susceptibility tests J Clin Microbiol 1992, 30 3138-3145
42. Fromtling RA, Galgiani JN, Pfaller MA, Espinel-Ingroff A, Bartizal KF, Barlett MS, ody BA, Frey C, Hall G, Roberts GD, Nolte FB, Odds FC, Rinaldi MG, Sugar AM, Villareal K Multicenter evaluation of a macrobroth antifungal susceptibility test for yeasts Antimicrob Agents Chemother 1993, 37 39-45
43. Pfaller MA Burmeister L, Bartlett MS, Rinaldi MG Multicenter evaluation of four methods of yeast inoculum preparation J Clin Microbiol 1988, 26:1437-1441
44. National Committee for Clinical Laboratory Standards, Reference method for broth dilution susceptibility testing of yeasts Proposed Standard. NCCLS document M27-P (ISBM 1-56238-186-5) NCCLS, 771 E Lancaster Avenue, Villanova, Pensylvania 19085, 1992
45. Espinel-Ingroff A , L Steel-Moore, Galgiani JN Evaluation of 80% inhibition standards for the determination of fluconazole MICs in three laboratories 1994, Diagn Microbiol Infect Dis 20 81-86
46. National Committee for Clinical Laboratory Standards Reference method for broth dilution antifungal susceptibility testing of yeasts Tentative standard. NCCLS document M27-T. NCCLS, 771 E Lancaster Avenue, Villanova, Pa 19085, 1995
47. Ghannoum MA, Ibrahim AS, Fu Y, Shafiq MC Edwards JE, Criddle RS Susceptibility testing of Cryptacoccus neoformans, a microdilution technique J Clin Microbiol 1992, 30. 2881-2886
48. Pfaller MA, Bale M, Buschelman B, Lancaster M, Espinel-Ingroff A Rex JH, Rinaldi MG, Cooper CR, McGinnis MR Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B. fluconazole- and flucytosine J Clin Microbiol 1995, 33 1104-1107
49. Pasarell L, McGinnis MR Viability of fungal cultures maintained at -70°C. J Clin Microbiol 1992, 30 100-1004
50. Espinel-Ingroff A, Kerkering TM, Goldson PR, Shadomy S Comparison study of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol 1991 29 1089-1094
51. Pfaller MA, Grant C, Morthland V, Rhine-Chalberg J. Comparative evaluation of alternative methods for broth dilution susceptibility testing of fluconazole against Candida albicans. J Clin Microbiol 1994, 32:506-509
52. Sewell DL, Pfaller MA Barry AL Comparison of broth macrodilution, broth microdilution, and E test antifungal susceptibility tests for fluconazole. J Clin Microbiol 1994, 32 2099-2102
53. Rex JN, Pfaller MA, Barry AL Nelson PW, Webb CD for the NlAID Mycoses Study Group, the Candidemia Study Group Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia Antimicrob Agents Chemother 1995 39 40-44
54. Anaissie E, Paetznick V, Bodey GP Fluconazole susceptibility testing of Candida albicans microtiter method that is independent of inoculum size temperature, and time of reading Antimicrob Agents Chemother 35 1641-1646
55. Pfaller MA, Messer SA, Coffmann S Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution method to test five antifungal agents including the new triazole D0870 J Clin Microbiol 1995, 33 1094-1097
56. Espinel-Ingroff A, Rodriguez-Tudela JL, Martínez-Suárez JV, Comparison of two microdilutionmethods with the reference macrodilution test M27-P for in vitro testing of fluconazole resistant and susceptible isolates of Candida albicans J Clin Microbiol 1995, 33 3154-3158
57. Rodríguez-Tudela JL Martinez-Suárez J Improved medium for fluconazole susceptibility testing of Candida albicans Antimicrob Agents Chemother 1994, 38:45-48
58. Rodríguez-Tudela JL, Martínez-Suárez J. Correlation of in vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients J Antimicrob Chemother 1995, 35:793-804
59. Espinel-Ingroff A Etest for antifungal susceptibility testing of yeasts Diagn Microbiol Infect Dis 1994, 19 217-220
60. Colombo AL, Barchiesi F, McGough DA, Rinaldi MG Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole susceptibility testing J Clin Microbiol 1995. 33:535-540
61. Espinel-Ingroff A, Pfaller M, Erwin ME, Jones RM. 1995 An interlaboratory evaluation of the Etest method for antifungal susceptibility testing of pathogenic yeasts for five antifungal agents using casitone agar and solidified RPMI-1640 medium with 2% dextrose J Clin Microbiol, April 1996
62. Polak A, Dixon DM In vitro/in vivo correlation of antifungal susceptibility testing using 5-fluorocytosine and ketoconazole as examples of two extremes, p 45-49 En RA Fromtliing (ed ), Recent trends in the discovery, development and evaluation of antifungal agents JR Prous Science Publisher, Barcelona Spain 1987
63. Stiller RL, Bennett JE, Schaler HJ, Wall HJ, Polak A, Stevens DA. Correlation of in vitro susceptibility test results with in vivo response flucytosine therapy in a systemic candidiasis model J Infect Dis 1983, 147 1070-1076
64. Espinel-Ingroff A, Kerkering TM. Spectrophotometic method of inoculum preparation for the in vitro susceptibility testing of filamentous fungi J Clin Microbiol 1991,29 393-394
65. Espinel-Ingroff A, Dawson K, Pfaller M, Anaissie E, Breslin B, Dixon D, Fothergill A, Peter J, Rinaldi M, Walsh T Comparative and collaborative evaluation of standardization antifungal susceptibility testing for filamentous fungi Antimicrob Agents Chemother 1995, 39 314-319
66. Espinel-Ingroff A, Farina DR, Bowden R Pfaller M, Rinaldi M, Walsh T, Chin X. Second NCCLS evaluation of antifungal susceptibility testing of filamentous fungi 35th Intersci Conf Antimicrob Agents Chemother 1995, (Abstr D37), p 73